MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgag059

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2026

Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules.

Castellanos Luz E, Bryan Julian, Ricarte-Filho Julio C, Franco Aime T, Alshalalfa Mohammed, Klopper Joshua P, Kloos Richard T, Waguespack Steven G

СтатьяВалидационное исследованиеПеревод пока не подготовлен

Аннотация

CONTEXT: The Afirma Genomic Sequencing Classifier (GSC) is validated in patients ≥ 21 years with a 96% negative predictive value for malignancy when GSC-(B)enign. Afirma GSC has not been formally studied in patients <21 years of age with indeterminate thyroid nodules (ITNs).

OBJECTIVE

To evaluate Afirma GSC in young patients with ITNs.

DESIGN

Retrospective analysis of Afirma GSC testing.

SETTING

ITNs referred for molecular testing in a real-world setting.

PARTICIPANTS

Forty-nine ITNs from 49 patients < 21 years of age who had histopathology or 2 years' clinical follow-up data ascertained.

INTERVENTION: None.

MAIN OUTCOME MEASURE: Afirma GSC test performance.

RESULTS

In 49 ITNs from patients aged 9 to 20 years (median 18.5 [interquartile range, 17.3-19.8]), 30 were GSC-B and 19 GSC-(S)uspicious, among which 14 (73.7%) were malignant (ie, true positive) and 5 (26.3%) were benign (ie, false positive). All 30 Afirma GSC-B cases were either histologically (n = 9) or clinically benign (n = 21) (ie, true negative). All 14 malignancies were GSC-S (sensitivity 100% [95% CI, 77-100]); 30/35 clinically or histologically benign cases were GSC-B (specificity 86% [95% CI, 70-95]). Negative predictive value for an Afirma GSC-B result was 100% [95% CI, 88-100]. Genomic alterations were not detected in the 30 GSC-B samples. Among the 14 malignant samples, there were 9 papillary thyroid carcinomas, 1 oncocytic carcinoma, 1 noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and 3 follicular thyroid carcinomas.

CONCLUSION

In young patients with ITNs, the Afirma GSC demonstrated an excellent negative predictive value when defining a thyroid nodule result by histology or clinical follow-up.

Для цитирования: Castellanos Luz E, Bryan Julian, Ricarte-Filho Julio C, Franco Aime T, Alshalalfa Mohammed, Klopper Joshua P, Kloos Richard T, Waguespack Steven G. Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules.. The Journal of clinical endocrinology and metabolism. 2026. DOI: 10.1210/clinem/dgag059.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.